NCT00523549

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 229 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)\<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7 recommended target SBP of \<140 mmHg on the intrinsic diastolic properties of the myocardium in patients with hypertension and echocardiographic evidence of diastolic dysfunction.

Conditions

• Hypertension
• Diastolic Dysfunction

Interventions

Type	Name	Description
DRUG	valsartan	160 mg or 320 mg tablets once a day
DRUG	amlodipine	5 mg or 10 mg tablets once a day

Timeline

• Start date: 2006-11-01
• Primary completion: 2008-01-01
• Completion: 2008-01-01
• First posted: 2007-08-31
• Last updated: 2012-04-23
• Results posted: 2011-03-10

Locations

1 site across 1 country: United States